We are live on ! Find out more
TRIB

Trinity Biotech

19 hedge funds and large institutions have $5.95M invested in Trinity Biotech in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, 4 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more capital invested

Capital invested by funds: $2.58M → $5.95M (+$3.37M)

0.03% more ownership

Funds ownership: 0.03%0.05% (+0.03%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

21% less funds holding

Funds holding: 2419 (-5)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
19
Holders Change
-5
Holders Change %
-20.83%
% of All Funds
0.27%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
7
Increased
Reduced
4
Closed
11
Calls
Puts
Net Calls
Net Calls Change

TRIB Hedge Fund Activity: Q1 2024 in Review

19 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q1 2024, worth a combined $5.95M — up 130% from $2.58M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of TRIB and 7 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 0 added.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $4.22M. The largest seller was Stonehill Capital Management, cutting an estimated $127K.

  • 19 institutional investors held Trinity Biotech (TRIB) as of Q1 2024, down from 24 in Q4 2023.
  • Funds reported $5.95M of Trinity Biotech stock for Q1 2024, up 130% quarter-over-quarter.
  • 7 funds opened new Trinity Biotech positions in Q1 2024 and 11 closed out, a net change of -4 holders.
  • The largest Trinity Biotech buyer in Q1 2024 was Perceptive Advisors, an estimated $4.22M added.
  • The largest Trinity Biotech seller in Q1 2024 was Stonehill Capital Management, an estimated $127K sold.

Based on aggregated 13F filings for Q1 2024.